e-Drug3D

2015

TEPOTINIB

INN
TEPOTINIB

cas 1100598-32-0

CLASS

ANTINEOPLASTIC
MET INHIBITOR
TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
INHIBITS MELATONIN 2 RECEPTOR AND IMIDAZOLINE 1 RECEPTOR

ROUTE (list)

ORAL

ATC code

L01EX21

PK parameters

F 71.6 PERCENT
Tmax 8 HOUR
VD 1038 LITER
Cl 23.8 LITER / HOUR
PPB 98 PERCENT
t1/2 32 HOUR

Target

TARGET MET KINASE

PDB
4R1V (IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS)

Download experimental 3D coordinates of 3E8 with added hydrogens

Hepatocyte growth factor receptor UNIPROT P08581 MET

Download SDF file

Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-

Formula:
C29H28N6O2

Calculated chemical properties:

MW 492.57
NB_atoms 37
XLogP 4.01
PSA 83.091
NB_HD 0
NB_HA 8
fsp3 0.28
Lipinski(0=no;1=yes) 1

FDA
NDA 214096 (label) INN (TEPOTINIB HYDROCHLORIDE) TEPMETKO (EMD SERONO INC) APPROVAL= AP YEAR= 2021